What Is Menopausal Hormone Therapy?

Menopausal hormone therapy replaces some of the estrogen, and sometimes progesterone, that the ovaries produce in lower and more erratic amounts during perimenopause and after menopause.

Menopause is officially diagnosed after 12 consecutive months without a menstrual period when another medical cause is not responsible. The years leading to that point are known as perimenopause. During this transition, hormone levels can fluctuate dramatically rather than declining in a calm, orderly line. The result can feel less like a gentle dimmer switch and more like someone flicking the lights on and off for several years.

MHT is primarily used to treat bothersome menopausal symptoms. Systemic therapy can also prevent bone loss while it is being taken, but hormone therapy should not be prescribed solely as a general anti-aging treatment or as a routine way to prevent heart disease, dementia, or other chronic conditions.

The Main Types of Menopausal Hormone Therapy

Estrogen-Only Therapy

Estrogen-only therapy is generally used by people who have had a hysterectomy and no longer have a uterus. Estrogen may be delivered through a pill, skin patch, gel, spray, vaginal ring, cream, tablet, or insert.

Systemic estrogen circulates throughout the body and can treat hot flashes, night sweats, and other widespread symptoms. Low-dose vaginal estrogen acts mainly in vaginal and urinary tissues and is used for localized symptoms.

Estrogen Plus a Progestogen

People who still have a uterus usually need a progestogen along with systemic estrogen. Progestogens include progesterone and synthetic progesterone-like medications known as progestins.

Estrogen stimulates the uterine lining. Without adequate protection, prolonged exposure can increase the risk of endometrial hyperplasia and endometrial cancer. Adding a progestogen helps prevent that excessive growth.

Local Vaginal Hormone Therapy

Low-dose vaginal estrogen is intended for genitourinary syndrome of menopause, or GSM. This condition may cause vaginal dryness, burning, painful sex, urinary urgency, and recurrent urinary tract infections.

Because low-dose vaginal products create much lower bloodstream exposure than systemic therapy, they have a different risk profile. Progestogen is generally not required with standard low-dose vaginal estrogen, although treatment should still be discussed with a clinician, particularly after a hormone-sensitive cancer.

What Symptoms Can MHT Treat?

Menopausal hormone therapy is the most effective available treatment for vasomotor symptoms, the medical term for hot flashes and night sweats. It may also improve sleep when nighttime symptoms are repeatedly launching the blankets across the room.

Depending on the formulation and individual circumstances, MHT may help with:

• Hot flashes and night sweats
• Sleep disruption related to vasomotor symptoms
• Vaginal dryness, irritation, or burning
• Pain during sexual activity
• Some urinary symptoms associated with GSM
• Menopause-related mood changes in selected patients
• Bone loss and fracture risk while systemic therapy is used

MHT is not a guaranteed solution for every midlife complaint. Fatigue, weight changes, low mood, poor concentration, and reduced sexual desire can have several causes. Thyroid disease, anemia, sleep apnea, medication effects, depression, and relationship stress do not disappear simply because an estrogen patch enters the building.

Who Is Most Likely to Benefit?

For many healthy people with bothersome symptoms, the benefit-risk balance is generally most favorable when systemic hormone therapy begins before age 60 or within approximately 10 years of menopause onset.

That guideline is not an expiration date stamped on a person’s forehead. It reflects evidence showing that age, time since menopause, cardiovascular health, and blood-clot risk influence safety. Starting systemic therapy for the first time at age 52 is not medically identical to starting it at age 72.

Potential candidates include people experiencing moderate or severe hot flashes, persistent night sweats, significant sleep disruption, bothersome GSM, or early loss of ovarian function. Those with primary ovarian insufficiency or surgical menopause may be advised to use hormone therapy until around the average age of natural menopause, provided they do not have a contraindication.

Benefits of Menopausal Hormone Therapy

Strong Relief From Hot Flashes

The clearest benefit is relief from vasomotor symptoms. Many users experience fewer and less intense hot flashes after finding an effective dose, although improvement is not always immediate.

Better Sleep and Daily Function

Reducing night sweats can improve sleep continuity, daytime energy, concentration, and overall quality of life. Hormones are not sleeping pills, but removing a 3 a.m. internal heat wave can make sleep considerably less adventurous.

Improved Vaginal and Urinary Comfort

Local vaginal treatment can restore moisture and tissue flexibility, reduce discomfort during sex, and ease certain urinary symptoms. GSM often persists or worsens without treatment, unlike hot flashes, which may eventually become less frequent.

Protection Against Bone Loss

Systemic estrogen slows the bone loss that accelerates after menopause and reduces fracture risk while therapy continues. Other osteoporosis medications may be more appropriate when bone protection is the only treatment goal.

Risks and Side Effects

The risks of MHT are not the same for every product or every patient. They can vary according to age, medical history, hormone type, route of administration, dose, treatment duration, and whether estrogen is used alone or with a progestogen.

Blood Clots and Stroke

Systemic hormone therapy may increase the risk of venous blood clots and stroke in some users. Oral estrogen generally has a greater effect on liver-produced clotting factors than estrogen absorbed through the skin. For people with certain cardiovascular or metabolic risk factors, a transdermal patch, gel, or spray may be preferred, although no route makes the risk zero.

Breast Cancer

Breast cancer risk depends partly on the treatment regimen and length of use. Combined estrogen-progestogen therapy has been associated with an increase in breast cancer risk with longer use. Estrogen-only therapy after hysterectomy has shown a different pattern in clinical trials and should not automatically be assigned the same risk estimate.

The choice of progestogen may also matter, but additional research is needed before every formulation can be ranked with certainty. Personal breast cancer risk, family history, breast density, previous biopsies, and screening history belong in the treatment conversation.

Endometrial Cancer

Systemic estrogen used without appropriate uterine protection increases endometrial cancer risk in someone who still has a uterus. This is why a progestogen, or another approved method of endometrial protection, is normally added.

Gallbladder Problems

Oral hormone therapy may raise the likelihood of gallbladder disease. Transdermal estrogen bypasses the initial trip through the liver and may be considered when gallbladder or metabolic risks are relevant.

Common Early Side Effects

Temporary side effects can include breast tenderness, bloating, nausea, headaches, mood changes, and spotting. These may settle as the body adjusts, but persistent or troublesome effects can indicate that the dose, schedule, delivery route, or progestogen needs to be changed.

The 2026 FDA Labeling Update

In February 2026, the U.S. Food and Drug Administration approved labeling changes for six menopausal hormone therapy products. Statements concerning cardiovascular disease, breast cancer, and probable dementia were removed from the products’ boxed warnings to provide more specific benefit-risk information.

The change did not declare that all forms of MHT are risk-free, nor did it erase the need for screening and individualized prescribing. It emphasized an important point: findings from older studies involving particular oral formulations and an older average participant population should not be applied indiscriminately to every hormone, route, dose, or patient.

Oral Estrogen vs. Transdermal Estrogen

Oral estrogen is convenient and effective, but it passes through the liver before entering the general circulation. This “first-pass” process can affect triglycerides, clotting proteins, and other liver-produced substances.

Transdermal estrogen is absorbed through the skin. Patches are commonly replaced once or twice a week, while gels and sprays are generally applied more frequently. Transdermal therapy may be favored for people with elevated triglycerides, migraines, obesity, gallbladder concerns, or increased blood-clot risk.

The best route is not determined by whichever product has the most calming packaging. It depends on symptoms, risk factors, preference, cost, insurance coverage, skin sensitivity, and the ability to follow the treatment schedule consistently.

Who Should Avoid Systemic Hormone Therapy?

Systemic MHT may be inappropriate or require specialist evaluation for people with:

• Unexplained vaginal bleeding
• A history of certain hormone-sensitive cancers
• Previous blood clots or a known serious clotting disorder
• A previous stroke or heart attack
• Active or significant liver disease
• Known or suspected pregnancy
• Other major cardiovascular risks that make treatment unsafe

These are not situations for do-it-yourself prescribing. A history of cancer does not create exactly the same recommendation for every person, but decisions may require collaboration among a gynecologist, menopause specialist, oncologist, or other appropriate clinician.

What About “Bioidentical” Hormones?

The word “bioidentical” refers to hormones with a chemical structure identical to hormones produced by the human body. Several FDA-approved estradiol and micronized progesterone products meet that definition.

Compounded bioidentical hormone therapy is different. Compounding may be useful when a patient has a genuine need that no approved product can meet, such as an allergy to a particular ingredient. However, custom-compounded hormones are not automatically safer, more natural, or more effective than FDA-approved products.

Compounded pellets, creams, and capsules may have less consistent dosing and lack the standardized safety, effectiveness, and manufacturing review required for approved medications. Saliva tests marketed as a way to create a “perfectly customized” dose are generally not useful because hormone levels fluctuate and symptoms do not consistently match a single laboratory measurement.

Starting and Monitoring Treatment

A menopause evaluation usually begins with a symptom history, menstrual history, medication review, and assessment of cardiovascular, clotting, cancer, liver, and bone-health risks. Routine hormone blood testing is usually unnecessary for otherwise typical perimenopausal symptoms.

Treatment is commonly started at a dose appropriate for the symptom burden and health profile. The objective is not necessarily the tiniest dose commercially available; it is the lowest effective dose that meets the individual treatment goal.

Follow-up may cover symptom improvement, bleeding, side effects, blood pressure, medication adherence, and whether the regimen remains appropriate. Breast and cervical cancer screening should continue according to current recommendations.

There is no universal rule requiring every patient to stop MHT at age 65. Continuing therapy can be reasonable for persistent symptoms or selected health goals after periodic review. Likewise, there is no medal for remaining on hormones forever. Treatment duration should be individualized rather than decided by birthday alone.

Nonhormonal Alternatives

People who cannot or prefer not to use systemic hormones still have evidence-based options. Certain antidepressants, gabapentin, oxybutynin, and neurokinin-targeting medications such as fezolinetant may reduce hot flashes. Each has its own benefits, side effects, interactions, and monitoring requirements.

For vaginal symptoms, nonhormonal moisturizers and lubricants may help. Prescription options can include low-dose vaginal estrogen, vaginal dehydroepiandrosterone, or oral ospemifene, depending on the person’s medical history.

Layered clothing, cooler bedrooms, regular physical activity, smoking cessation, and reducing personal hot-flash triggers can support treatment. They may not replace medication for severe symptoms, but they can keep the thermostat negotiations slightly more civilized.

Common Experiences With Menopausal Hormone Therapy

The following examples are illustrative composites based on experiences commonly discussed in clinical care. They are not individual patient histories and should not be treated as personalized medical recommendations.

Experience 1: “I Finally Slept Through the Night”

A 51-year-old in late perimenopause might seek care after months of waking soaked in sweat several times a night. She may feel irritable, forgetful, and worried that she is becoming less capable at work. After discussing her history and confirming a low baseline risk for cardiovascular disease and blood clots, her clinician may prescribe transdermal estradiol with oral micronized progesterone because she still has a uterus.

During the first few weeks, she may notice breast tenderness or mild spotting. By the second month, her night sweats may become less frequent and her sleep may improve. The biggest change may not be a dramatic feeling of “more estrogen.” It may simply be waking up rested enough to remember why she entered the kitchen.

Experience 2: “The First Prescription Was Not the Final Prescription”

A 48-year-old with severe hot flashes may begin an oral estrogen-progestin product and experience nausea, bloating, or mood changes. That does not necessarily mean all hormone therapy is unsuitable. Her clinician might lower the dose, change the progestogen, or move from oral estrogen to a patch.

Menopausal hormone therapy often requires adjustment. Bodies are inconveniently uninterested in standardized scripts. One patient may feel well on a low-dose patch, while another needs a different dose or regimen. Reporting side effects early helps the clinician distinguish a temporary adjustment period from a treatment mismatch.

Experience 3: “My Hot Flashes Were Mild, but Sex Hurt”

A 60-year-old who has been postmenopausal for several years may have no meaningful hot flashes but develop vaginal dryness, irritation, and painful sex. She may assume that systemic hormones are the only hormonal option and decide treatment feels too risky.

After evaluation, she may learn that low-dose vaginal estrogen treats local tissues with minimal systemic absorption. A cream, tablet, insert, or ring may improve comfort over several weeks. Vaginal moisturizers can provide additional support. This experience illustrates why the treatment should match the symptom: a whole-body therapy is not always needed for a local problem.

Experience 4: “I Wanted Hormones, but My History Changed the Plan”

A 56-year-old with disruptive hot flashes may arrive expecting an estrogen prescription but report a previous blood clot. Her clinician may explain that systemic estrogen could add unacceptable risk. Instead, they might discuss nonhormonal medications, cooling strategies, sleep support, and treatment of any coexisting anxiety or depression.

The patient may initially feel disappointed, particularly after hearing glowing stories from friends. Yet successful menopause care is not defined by receiving hormones. It is defined by finding the safest treatment that produces meaningful relief.

Experience 5: “I Was Afraid to Continue After 65”

A long-term user may approach her 65th birthday believing she must stop immediately. Her hot flashes may still be severe whenever she reduces the dose. After reviewing her current health, screening history, preferences, and treatment route, her clinician may recommend continuing at the existing dose, trying a gradual reduction, or switching to another formulation.

Another person with new cardiovascular or cancer-related concerns might make a different choice. The lesson is that MHT decisions should be revisited, not dictated by an arbitrary cutoff. Continuing therapy is not automatically reckless, and stopping it is not automatically virtuous. The useful question is whether the current benefits still outweigh the current risks for the individual sitting in the exam room.

Across these experiences, the recurring theme is personalization. Menopausal hormone therapy works best when the prescription reflects the symptom being treated, whether the uterus is present, the person’s medical history, and the route and dose most appropriate for that risk profile. It is a process of informed adjustment, not a one-size-fits-all rescue package.

Conclusion

Menopausal hormone therapy can be a highly effective treatment for hot flashes, night sweats, sleep disruption, vaginal discomfort, and other menopause-related symptoms. For many healthy people who begin treatment near the menopause transition, the benefits may outweigh the risks.

The safest plan depends on far more than age. The presence of a uterus, personal and family medical history, treatment route, dose, formulation, and individual priorities all matter. A careful conversation with a qualified clinician can separate genuine risks from outdated generalizations and help identify whether systemic hormones, local therapy, or a nonhormonal option is the best fit.